Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA

Pituitary

Volumn 10, Issue 3, 2007, Pages 227-232

  De Marinis, Laura ^a   Bianchi, Antonio ^a   Fusco, Alessandra ^a   Cimino, Vincenzo ^a   Mormando, Marilda ^a   Tilaro, Laura ^a   Mazziotti, Gherardo ^b   Pontecorvi, Alfredo ^a   Giustina, Andrea ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Acromegaly; Combined therapy; Glucose metabolism; Pegvisomant; Somatostatin analogs

Indexed keywords

CORTISONE ACETATE; ESTROGEN; GLUCOSE; HEMOGLOBIN; INSULIN; LEVOTHYROXINE; OCTREOTIDE; ORAL ANTIDIABETIC AGENT; PEGVISOMANT; SOMATOMEDIN; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOPITUITARISM; INSULIN RESPONSE; LONG TERM CARE; LONGITUDINAL STUDY; LYMPHOCYTE FUNCTION; MALE; MONOTHERAPY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROGNOSIS;

ACROMEGALY; ADULT; BLOOD GLUCOSE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LONG-TERM CARE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SOMATOSTATIN;

EID: 35848967790     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-007-0037-7     Document Type: Article

References (30)

1. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metabol 89:667-674
2. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salamela P, Salmi J, Stenman UH, Viikari J, Voutilainen E (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metabol 90:4081-4086
3. Clayton RN (2003) Cardiovascular function in acromegaly. Endocrine Review 24:272-277
4. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: Epidemiology, pathogenesis, and management. Endocrine Rev 25:102-152
5. Kuller LH, Velentgas P, Barzilay J, Beauchamp NJ, O'Leary DH, Savane PJ (2000) Diabetes mellitus: Subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. Arter Thromb Vasc Biol 20:823-829
6. Clemmons DR (2004) The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest 113:25-27
7. Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S (2003) The pituitary society, the european neuroendocrine association: Diagnosis and treatment of acromegaly complications J Endocrin Invest 26:1242-1247
8. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A (2005) Consensus statement: Medical management of acromegaly. Eur J Endocrinol 153:737-740
9. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D (2005) Long-acting somatostatin analog therapy of acromegaly: A meta-analysis. J Clin Endocrinol Metabol 90:4465-4473
10. Baldelli R, Battista C, Legnetti F, Ghigni MR, Ribaldo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburano G (2003) Glucose homeostasis in acromegaly: Effects of long-acting somatostatin analogues treatment. Clin Endocrinol 59:492-499
11. Pereira AM, Biermasz NR, Roelfsema F, Romijn JA (2005) Pharmacologic therapies for acromegaly: A review of their effects on glucose metabolism and insulin resistance. Treat Endocrinol 4:43-53
12. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barman AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N E J Med 342:1171-1177
13. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ (2000) Growth hormone receptor antagonists: Discovery, development, and use in patients with acromegaly. Endocrine Rev 23:623-646
14. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 24:1754-1759
15. Stewart PM (2003) Pegvisomant: An advance in clinical efficacy in acromegaly. Eur J Endocrinol 148:S27-S32
16. Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metabol 87:1692-1699
17. Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP, Trainer PJ (2003) Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur J Endocrinol 149:521-527
18. Barkan AL, Barman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML (2005) Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metabol 90:5684-5691
19. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Barman P, Kourides IA, Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: Effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467-477
20. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C, Orskov H (2005) Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrino Metabol 90:5627-5631
21. Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A (2006) Resistance to somatostatin analogs in acromegaly: An evolving concept? J Endocrinol Invest 29:86-93
22. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365:1644-1646
23. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A (2002) Guidelines for acromegaly management. J Clin Endocrinol Metabol 87:4054-4058
24. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: A consensus statement. J Clin Endocrinol Metabol 85:526-529
25. American Diabetes Association (2006) Standards of Medical Care in Diabetes Diabetes Care 29:S4-S42
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
27. Bertoli A, Magnaterra R, Borboni P, Marini MA, Barini A, Fusco A, Bollea MR (1998) Dose-dependent effect of octreotide on insulin secretion after OGTT in obesity. Hormone Res 49:17-21
28. Ronchi CL, Orsi E, Giavoli C, Cappiello V, Epaminonda P, Beck-Peccoz P, Arosio M (2003) Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. J Endocrinol Invest 26:533-538
29. Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, Trainer PJ (2002) A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metabol 87:1797-1804
30. Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T, Arita N (2000) Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrino 52:549-555